Injectable Solutions That Meet Treatment Goals in nAMD and DME Management is organized by Healio.
Release Date: October 31, 2023
Expiration Date: October 30, 2024
Activity Description:
New therapies that are available for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) increasingly allow for longer treatment intervals and lower patient burden. This is because advancements in targeted anti-vascular endothelial growth factor (VEGF) therapies and newer dual VEGF/angiopoietin-2 inhibitors have resulted in enhanced visual acuity and durability as well as non-inferior outcomes to traditional therapies. In addition to utilizing injectable regimens that allow for increased treatment intervals, comprehensive ophthalmologists and other healthcare professionals should choose appropriate therapy based on safety and efficacy. In this CE activity, expert faculty compare injectable treatment regimens and present strategies for optimal treatment selection using protocols that account for overall efficacy, safety, and durability.
Learning Objectives:
Upon successful completion of this activity, participants should be better able to:
• Compare injectable treatment regimens that offer increased longevity in patients with nAMD and DME.
• Optimize treatment selection by using protocols that offer increased efficacy, safety, and durability in patients with nAMD and DME.